Sign in

STAA on Nasdaq

STAAR SURGICAL CO

American ophthalmic goods company based in Monrovia, listed on Nasdaq (STAA)2

In its 2026 annual report the company says: “We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or “refractive” surgery. We have been dedicated solely to ophthalmic surgery for over 40 years. We market and sell our ICLs for refractive surgery to treat myopia (nearsightedness) as our “EVO” family of lenses.”6

Price unavailable

Last updated Oct 21, 2026.

Overview

$239.4MRevenue, fiscal 20263
-$80.4MNet income, fiscal 20263

Compare with RxSight, Inc., Warby Parker or National Vision Holdings, Inc., or pick any stock.

  • TickerSTAA on Nasdaq2
  • IndustryOphthalmic Goods2
  • HeadquartersMonrovia, United States2
  • Incorporated inDE4
  • Business address1911 Walker Ave, Monrovia, Ca 910164
  • Filer categoryLarge accelerated filer4
  • Legal formCorporation2
  • LEI5299006LRHI7OJ8BY3082
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o Corporation Service Company, 251 Little Service Company, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 20874872

See how the biggest companies compare on our leaderboards

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or “refractive” surgery. We have been dedicated solely to ophthalmic surgery for over 40 years. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. Unless the context indicates otherwise, “we,” “us,” the “Company,” and “STAAR” refer to STAAR Surgical Company and its consolidated subsidiaries.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

76.2%Gross margin3
-38.3%Operating margin3
-33.6%Net margin3
-23.4%Return on equity3
-$40.0MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue15¢$57.0M
  • Research and development11¢$40.1M
  • Selling, general and admin73¢$274.1M
  • Income tax0¢$1.8M

Out of $239.4M in revenue.3 The company lost money this year.

Financial statements

Revenue783$239.4M in 2026+1048% since 2020
0$100.0M$200.0M$300.0M$400.0M2020: $20.9M$20.9M20202021: $230.5M$230.5M2021+1005%2022: $239.4M$239.4M2022+4%2023: $322.4M$322.4M2023+35%2024: $313.9M$313.9M2024−3%2026: $239.4M$239.4M2026−24%
Gross profit98103$182.4M in 2026+63% since 2020
0$100.0M$200.0M$300.0M2020: $112.0M$112.0M20202021: $178.6M$178.6M2021+60%2022: $223.4M$223.4M2022+25%2023: $252.7M$252.7M2023+13%2024: $239.6M$239.6M2024−5%2026: $182.4M$182.4M2026−24%
Operating income98103-$91.7M in 2026
-$100.0M-$50.0M0$50.0M2020: $11.9M$11.9M20202021: $33.3M$33.3M2021+181%2022: $43.8M$43.8M2022+31%2023: $28.1M$28.1M2023−36%2024: -$12.6M-$12.6M20242026: -$91.7M-$91.7M2026+627%
Net income98103-$80.4M in 2026
-$100.0M-$50.0M0$50.0M2020: $14.0M$14.0M20202021: $27.5M$27.5M2021+96%2022: $39.7M$39.7M2022+44%2023: $21.3M$21.3M2023−46%2024: -$20.2M-$20.2M20242026: -$80.4M-$80.4M2026+298%
Fiscal year20192020202120222023202420252026
Revenue$20.9M7$230.5M8$239.4M3$322.4M3$313.9M3$239.4M3
Cost of revenue$38.2M9$51.8M8$61.0M10$69.8M3$74.3M3$57.0M3
Gross profit$112.0M9$178.6M8$223.4M10$252.7M3$239.6M3$182.4M3
Research and development$25.3M9$33.9M8$36.0M10$40.5M3$45.3M3$40.1M3
Selling, general and admin$100.1M9$145.3M8$179.6M10$224.6M3$252.2M3$274.1M3
Operating income$11.9M9$33.3M8$43.8M10$28.1M3-$12.6M3-$91.7M3
Interest
Income before tax$31.3M8$45.6M10$33.7M3-$9.1M3-$82.3M3
Income tax-$1.0M9$3.8M8$5.9M10$12.3M3$11.2M3-$1.8M3
Net income$14.0M9$27.5M8$39.7M10$21.3M3-$20.2M3-$80.4M3
Earnings per share$0.329$0.588$0.8310$0.443-$0.413-$1.623
Earnings per share (diluted)$0.309$0.568$0.8010$0.433-$0.413-$1.623
Shares (weighted, basic)47.2M shares848.0M shares1048.5M shares349.1M shares349.6M shares3
Shares (weighted, diluted)49.5M shares849.4M shares1049.4M shares349.1M shares349.6M shares3

Compare STAAR SURGICAL CO with another company

Corporate structure

STAAR SURGICAL CO sits at the top of its group. 6 entities, 5 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of STAAR SURGICAL CO

  • STAAR SURGICAL CO Monrovia, California, United States
    • STAAR Japan Inc. Subsidiary · Japan
    • STAAR Optical Equipment Technology (Shanghai) Co., LTD Subsidiary · China
    • STAAR Surgical CHINA CO., LTD Subsidiary · China
    • STAAR Surgical India Private Limited Subsidiary · India
    • STAAR Surgical UK LTD Subsidiary · United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What STAAR SURGICAL CO reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$45.1M3 Jan 2, 2026$46.1M3 Dec 27, 2024−2.1%
Furniture and fixtures$7.5M3 Jan 2, 2026$7.6M3 Dec 27, 2024−1.9%
Computer equipment and software$31.5M3 Jan 2, 2026$15.8M3 Dec 27, 2024+100.0%
Leasehold improvements$19.4M3 Jan 2, 2026$19.8M3 Dec 27, 2024−1.8%
Construction in progress$30.3M3 Jan 2, 2026$32.0M3 Dec 27, 2024−5.2%
Property and equipment, before depreciation$112.9M3 Jan 2, 2026$118.5M3 Dec 27, 2024−4.7%
Accumulated depreciation$39.6M3 Jan 2, 2026$33.6M3 Dec 27, 2024+17.7%
Property and equipment, net$73.3M3 Jan 2, 2026$84.9M3 Dec 27, 2024−13.6%
Finance-lease assets$37.0K3 Dec 27, 2024$183.0K10 Dec 29, 2023−79.8%
Operating-lease assets (leased space)$29.6M3 Jan 2, 2026$36.9M3 Dec 27, 2024−19.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$153.2M3 Jan 2, 2026$144.2M3 Dec 27, 2024+6.2%
Marketable securities, current$34.4M3 Jan 2, 2026$86.3M3 Dec 27, 2024−60.2%
Debt securities available for sale$34.4M3 Jan 2, 2026$86.3M3 Dec 27, 2024−60.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.8M3 Jan 2, 2026$1.8M3 Dec 27, 20240%

Inventory

ItemLatestA year beforeChange
Raw materials$10.2M3 Jan 2, 2026$9.7M3 Dec 27, 2024+5.5%
Work in process$8.5M3 Jan 2, 2026$8.2M3 Dec 27, 2024+4.2%
Finished goods$39.7M3 Jan 2, 2026$26.7M3 Dec 27, 2024+48.5%

Properties, in its own words

Our operations are conducted in leased facilities throughout the world. STAAR maintains operational and administrative facilities in the U.S., Switzerland, and Japan. Our global administrative offices, principal manufacturing, warehouse, and distribution facilities are located in Monrovia, California. We manufacture the raw material for Collamer lenses in our facility in Aliso Viejo, California. STAAR also operates a technology center housing its research and development (R&D) team and labs in Tustin, California. Our corporate headquarters, including our executive offices, our EVO Experience Center, and additional operational facilities, are located in Lake Forest, California. STAAR Surgical AG maintains administrative offices, warehouse and distribution facilities in Nidau and Brügg, Switzerland. We are in the process of expanding our manufacturing capabilities for STAAR’s ICL products in our Nidau, Switzerland facility. STAAR Japan maintains administrative offices in Tokyo and Osaka, Japan and a distribution facility in Musashino City, in greater Tokyo, Japan. We also maintain commercial offices in China, Germany, Spain, India, Singapore, and the U.K.

We believe our existing properties are well maintained, in good operating condition and are adequate to support our present level of operations. We also believe that we could increase capacity as needed.

Item 2 of the 10-K filed Mar 3, 2026.6

Leadership

Who has led STAAR SURGICAL CO, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Barry G. Caldwell2008–2012
  2. Caren L. Mason2015–2022
  3. Thomas G. Frinzi2023–2025
  4. Stephen C. Farrell2025–2026
  5. Deborah J. Andrews2026–now
  6. Warren Foust2026–now

President

  1. Barry G. Caldwell2008–2012
  2. Isamu Kamijo2010
  3. Donald J. Todd2010–2012
  4. Hans-Martin Blickensdoerfer2015
  5. Caren L. Mason2015–2022
  6. Thomas G. Frinzi2023–2025
  7. Stephen C. Farrell2025
  8. Warren Foust2025–now

Chief financial officer

  1. Deborah J. Andrews2006–2016
  2. Stephen P. Brown2016–2017

Chief operating officer

  1. Warren Foust2023–now
2010201520202025
Board members and other officers (47)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • STAAR Japan Inc. Japan5
  • STAAR Optical Equipment Technology (Shanghai) Co., LTD China5
  • STAAR Surgical AG Switzerland5
  • STAAR Surgical CHINA CO., LTD China5
  • STAAR Surgical India Private Limited India5
  • STAAR Surgical PTE. LTD Singapore5
  • STAAR Surgical UK LTD United Kingdom5

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • STAAR SURGICAL COMPANYAug 10, 1995 to Aug 17, 20044

Timeline

  1. Oct 5, 20268-K Executive or director change; Regulation FD disclosure78
  2. Sep 10, 20268-K Executive or director change; Regulation FD disclosure79
  3. Aug 12, 20268-K Results of operations; Regulation FD disclosure80
  4. Aug 6, 20268-K Executive or director change; Regulation FD disclosure81
  5. Jun 22, 20268-K Executive or director change; Shareholder vote82
  6. Jun 9, 20268-K Executive or director change83
  7. May 13, 20268-K Results of operations; Regulation FD disclosure84
  8. Apr 8, 20268-K Regulation FD disclosure85
  9. Mar 3, 20268-K Results of operations; Regulation FD disclosure86
  10. Feb 5, 20268-K Executive or director change87
  11. Feb 4, 2026New chief executive Warren Foust becomes CEO18
  12. Feb 4, 2026New chief executive Deborah J. Andrews becomes CEO17
  13. Feb 2, 20268-K Executive or director change; Regulation FD disclosure88
  14. Jan 16, 20268-K Executive or director change89
  15. Feb 28, 2025New chief executive Stephen C. Farrell becomes CEO19
  16. Jan 4, 2023New chief executive Thomas G. Frinzi becomes CEO20
  17. Mar 4, 2015New chief executive Caren L. Mason becomes CEO21
  18. Jan 10, 2008New chief executive Barry G. Caldwell becomes CEO22

Calendar

Coming up

  1. Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.30 a share, on Nov 5, 2025.90

When it reported results

  1. Aug 12, 2026Reported quarterly or annual results80
  2. May 13, 2026Reported quarterly or annual results84
  3. Mar 3, 2026Reported quarterly or annual results86
  4. Nov 5, 2025Reported quarterly or annual results91
  5. Oct 20, 2025Reported quarterly or annual results92
  6. Aug 6, 2025Reported quarterly or annual results93
  7. May 7, 2025Reported quarterly or annual results94
  8. Feb 11, 2025Reported quarterly or annual results95

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

434 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 86 major events, 174 insider forms, 53 large holders, 101 other. The latest 20:

  1. Oct 5, 20268-K/A EDGAR
  2. Sep 10, 20268-K EDGAR
  3. Aug 18, 20264 EDGAR
  4. Aug 18, 20264 EDGAR
  5. Aug 18, 20264 EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 12, 202610-Q EDGAR
  8. Aug 12, 20268-K EDGAR
  9. Aug 6, 20268-K EDGAR
  10. Aug 4, 20264 EDGAR
  11. Aug 4, 20264 EDGAR
  12. Jun 24, 2026S-8 EDGAR
  13. Jun 23, 20264 OWNERSHIP DOCUMENT EDGAR
  14. Jun 22, 20264 EDGAR
  15. Jun 22, 20264 EDGAR
  16. Jun 22, 20264 EDGAR
  17. Jun 22, 20264 EDGAR
  18. Jun 22, 20264 EDGAR
  19. Jun 22, 20264 EDGAR
  20. Jun 22, 20268-K EDGAR

The 434 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

83 open-market trades by officers, directors and large owners since October 2021: 70 buys and 13 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 13, 2026BROADWOOD CAPITAL INC10% ownerBuy316,017$18.62$5.9MForm 4
Mar 12, 2026BROADWOOD CAPITAL INC10% ownerBuy299,432$18.12$5.4MForm 4
Mar 11, 2026BROADWOOD CAPITAL INC10% ownerBuy54,764$17.52$959.5KForm 4
Jan 9, 2026Bradsher Neal CDirectorBuy27,485$22.05$606.0KForm 4
Jan 8, 2026Bradsher Neal CDirectorBuy3,240$21.94$71.1KForm 4
Jan 7, 2026Bradsher Neal CDirectorBuy66,467$22.00$1.5MForm 4
Jan 6, 2026Bradsher Neal CDirectorBuy336,946$21.62$7.3MForm 4
Nov 21, 2025Bradsher Neal CDirectorBuy797,486$27.86$22.2MForm 4
Nov 20, 2025Bradsher Neal CDirectorBuy393,382$27.14$10.7MForm 4
Nov 19, 2025Bradsher Neal CDirectorBuy309,132$26.42$8.2MForm 4
Apr 10, 2025Bradsher Neal CDirectorBuy900$15.18$13.7KForm 4
Apr 9, 2025Bradsher Neal CDirectorBuy8,200$15.08$123.7KForm 4
Apr 8, 2025Bradsher Neal CDirectorBuy178,127$15.32$2.7MForm 4
Apr 7, 2025BROADWOOD PARTNERS, L.P.DirectorBuy138,054$15.61$2.2MForm 4
Apr 4, 2025BROADWOOD PARTNERS, L.P.DirectorBuy497,631$15.91$7.9MForm 4
Apr 3, 2025BROADWOOD PARTNERS, L.P.DirectorBuy209,535$16.97$3.6MForm 4
Apr 2, 2025BROADWOOD PARTNERS, L.P.DirectorBuy31,780$17.43$553.9KForm 4
Mar 31, 2025BROADWOOD PARTNERS, L.P.DirectorBuy22,189$17.46$387.4KForm 4
Mar 28, 2025Bradsher Neal CDirectorBuy8,131$17.47$142.0KForm 4
Mar 27, 2025Bradsher Neal CDirectorBuy3,620$17.48$63.3KForm 4

All 83 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Stephen C. Farrell$580.0K$7.5M106
2025Warren Foust$594.2K$4.4M106
2025Nathaniel Sisitsky$488.8K$2.8M106
2025Magda Michna$516.8K$2.7M106
2025Deborah Andrews$810.2K$2.6M106
2025Thomas G. Frinzi$167.2K$1.3M106
2025Patrick F. Williams$146.1K$926.9K106
2024Former President and Chief$820.0K$7.8M106
2024President and$570.7K$2.9M106
2024Former Chief Financial Officer$569.2K$2.9M106
2024Chief Development Officer$492.9K$2.3M106
2024Chief Legal Officer and$470.0K$2.1M106
2023Executive Officer$788.5K$10.2M106
2023Chief Operating Officer$359.6K$3.3M106
2023Former Chief Financial Officer$541.4K$2.8M106

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Broadwood Capital Inc16,123,842$462.6M24.2%No change
BlackRock, Inc.6,731,154$193.1M0.0%+65,036
Madison Avenue Partners, LP4,175,748$119.8M5.2%+1,734,070
Yunqi Capital Ltd3,257,130$93.4M74.8%No change
Point72 Asset Management, L.P.2,437,446$69.9M0.1%+1,614,294
Goldman Sachs Group Inc2,150,809$61.7M0.0%+1,080,870
Vanguard Portfolio Management LLC1,979,573$56.8M0.0%−144,016
State Street Corp1,769,354$50.8M0.0%−63,642
Anatole Investment Management Ltd1,651,701$47.4M8.0%+50,000
Vanguard Capital Management LLC1,552,743$44.5M0.0%−137,863
Morgan Stanley1,316,119$37.8M0.0%−183,237
Geode Capital Management, LLC1,076,006$30.9M0.0%+59,502
Two Seas Capital LP1,064,389$30.5M1.2%+27,416
Dimensional Fund Advisors LP867,142$24.9M0.0%+46,360
American Capital Management Inc846,659$24.3M1.1%−31,376
AI-Squared Management Ltd542,420$15.6M8.3%+274,336
Charles Schwab Investment Management Inc445,713$12.8M0.0%+37,137
Defender Capital, LLC.431,187$12.4M4.0%−213,355
Northern Trust Corp423,112$12.1M0.0%+22,894
Norges Bank365,200$10.5M0.0%New
UBS Group AG341,183$9.8M0.0%+161,254
Renaissance Technologies LLC340,400$9.8M0.0%+205,200
Defilade Capital Management, L.P.322,126$9.2M1.2%New
Vanguard Fiduciary Trust Co322,004$9.2M0.0%−66
Principal Financial Group Inc241,976$6.9M0.0%+1

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How STAAR SURGICAL CO is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSTAAR SURGICAL CO1
  • CIK0000718937
  • Employer ID (EIN)95-37974396
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company6
  • Incorporated inDelaware6
  • Fiscal year endsJanuary 21
  • Industry code (SIC)3851 Ophthalmic Goods1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address1911 Walker Ave, Monrovia, CA 910161
  • Phone62630379021
  • Shares outstanding50,143,984 as of Aug 7, 202613
  • Public float$883.9M as of Jun 27, 20256
  • AuditorBDO USA, P.C., Los Angeles, California PCAOB ID 243; it also attests to the company’s internal control over financial reporting6
  • On EDGAR sinceMay 2, 19951
  • Filings1,754 in all: 4 (654), 8-K (396), 10-Q (95), SC 13G/A (90), 3 (56), DEFA14A (52), DFAN14A (36), SC 13G (33)1
    All 50 form types

    DEF 14A (32), SC 13D/A (32), 10-K (29), UPLOAD (26), 4/A (23), CORRESP (23), SCHEDULE 13D/A (20), S-8 (17), S-3 (13), S-3/A (13), 8-K/A (11), 10-K/A (10), PRE 14A (9), SCHEDULE 13G/A (9), EFFECT (8), PX14A6G (8), 424B3 (6), 10-Q/A (5), ARS (5), S-8 POS (5), 424B5 (4), NT 10-K (4), SCHEDULE 13G (4), 144 (3), NT 10-Q (3), 10-K405 (2), REGDEX (2), SC 13D (2), 3/A (1), 424B2 (1), 5 (1), 5/A (1), 8-A12G/A (1), CT ORDER (1), DEFC14A (1), DEFM14A (1), NT 10-K/A (1), PREC14A (1), PREM14A (1), PRES14A (1), S-3MEF (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Mar 3, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) May 4, 2026
    Latest 8-K (8-K) Sep 10, 2026

Securities registered for trading

ClassSymbolExchange
CommonSTAANASDAQ

From the cover page of the 10-K filed Mar 3, 2026 (Section 12(b) of the Exchange Act).6

Risk factors and legal proceedings

The risks STAAR SURGICAL CO names in Item 1A of its 10-K filed Mar 3, 2026: 41 risks under these headings, as written.6

  • Risks Related to Our Business
  • We reported a decrease in revenue and a net loss in fiscal 2025 and 2024, and we may not be able to return to our growth and profitability trajectory.
  • Our reliance on independent distributors in international markets exposes us to commercial and other risks.
  • A slowdown or disruption to the Chinese economy or worsening trade relations between the U.S. and China could materially impact our business and results of operations.
  • Unfavorable economic conditions or negative publicity concerning complications of laser eye surgery, or medical devices in general, could hurt sales of our refractive products.
  • Disruptions in our supply chain or failure to adequately forecast product demand could result in significant delays or lost sales.
  • Because our business is global, our sales and profits may fluctuate or decline in response to changes in foreign currency exchange rates and/or other international risks, including tariffs.
  • Changes in our effective tax rate or additional tax liabilities could adversely impact our net income.
  • Changes in tax laws could result in additional tax liabilities.
  • We are vulnerable to any loss of use of our principal manufacturing facility.
  • Public health crises, political crises, and other catastrophic events or other events outside of our control may impact our business.
  • The loss of key employees, or our inability to recruit, hire and retain skilled and experienced personnel, could negatively impact our ability to effectively manage and expand our business.
The other 30 risks
  • We compete with much larger companies and low-cost Asian manufacturers.
  • We could experience losses due to product liability claims.
  • Our defined benefit pension plans are currently underfunded and we may be subject to significant increases in pension benefit obligations under those pension plans.
  • Our activities involve hazardous materials, emissions, and use of an irradiator and may subject us to environmental liability.
  • Data corruption, cyber-based attacks or network security breaches and/or noncompliance with data protection and privacy regulations could negatively impact our operations.
  • The increased use of social media platforms and mobile technologies presents additional risks and challenges.
  • Acquisitions of technologies, products, and businesses could disrupt our operations, involve increased expenses and present risks not contemplated at the time of the transactions.
  • If we are not able to manage growth successfully, it could adversely affect our business, financial condition, and results of operations.
  • Corporate responsibility, specifically related to environmental, social and governance (ESG) matters, may impose additional costs, expose us to reputational and emerging areas of risks, and could negatively affect our business.
  • Climate changes and extreme weather conditions could negatively affect our business.
  • Risks Related to the Ophthalmic Products Industry
  • Unless we keep pace with advances in our industry and persuade physicians to adopt our new products, our sales will not grow and may decline.
  • Resources devoted to research and development may not yield new ophthalmic products that achieve regulatory approval or commercial success.
  • We may be required to conduct extensive clinical trials to demonstrate safety and effectiveness of new or enhanced ophthalmic products, such clinical trials are expensive, complex, can take years to complete, and have highly uncertain outcomes.
  • Complying with government regulation substantially increases the cost of developing, manufacturing and selling our ophthalmic products.
  • We depend on proprietary technology, but our intellectual property protections may be limited.
  • We may not successfully replace our existing products, including those that lose or have lost patent protection.
  • While we will continue developing intellectual property protections for our future products, third parties may pursue blocking patents that limit our ability to manufacture such products.
  • Risks Related to Regulatory and Compliance
  • We are subject to extensive government regulation worldwide, which increases our costs and could prevent us from selling our products.
  • Regulatory issues may adversely impact our operations.
  • Laws pertaining to healthcare fraud and abuse could materially adversely affect our business, financial condition, and results of operations.
  • If we recall a product, the cost and damage to our reputation could harm our business.
  • Changes in U.S. FDA or international regulations related to product approval, including those that apply retroactively, could make us less competitive and harm our business.
  • If our products cause or contribute to a death or a serious injury, we may face voluntary corrective actions, agency enforcement actions and harm to our results.
  • If we modify our products, we may have to obtain new marketing clearances or approvals or may have to cease marketing or recall the modified products until clearances or approvals are obtained.
  • Non-compliance with anti-corruption laws could lead to penalties or harm our reputation.
  • Investigations and allegations, whether or not they lead to enforcement action or litigation, can materially harm our business and our reputation.
  • Risks Related to Ownership of Our Common Stock
  • The market price of our common stock has been and will likely continue to be volatile.
  • Because we do not intend to pay dividends, stockholders will benefit from an investment in our common stock only if it appreciates in value.
  • Ownership of our common stock is concentrated among a few investors, which may affect the ability of a third party to acquire control of us. Substantial sales by such investors could cause our common stock price to decline.
  • Future sales of our common stock could reduce our stock price.

Legal proceedings

See Note 13 – Commitments and Contingencies – Litigation and Claims to the Consolidated Financial Statements in this Annual Report on Form 10-K for information about Litigation and Claims, which is hereby incorporated by reference.

The opening of Item 3, Legal Proceedings.6

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
  98. 98
  99. 99
  100. 100
  101. 101
  102. 102
  103. 103
  104. 104
  105. 105
  106. 106